Larimar Therapeutics, Inc.

LRMR · Nasdaq · SIC 2834: Pharmaceutical Preparations
231
SEC Filings

Business Summary

PART I Overview We are a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using our novel cell penetrating peptide (CPP) technology platform. Our lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients a...

Next Earnings

Q2 FY2026 — expected 2026-09-25

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionLRMRdiscussed_in_filing Cybersecurity
topic_mentionLRMRdiscussed_in_filing Cybersecurity
topic_mentionLRMRdiscussed_in_filing Platform & Ecosystem
topic_mentionLRMRdiscussed_in_filing Platform & Ecosystem

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-192025-12-310001193125-26-115878EDGAR90K words
2025-03-242024-12-310000950170-25-043925EDGAR—
2024-03-142023-12-310000950170-24-031529EDGAR—
2023-03-142022-12-310000950170-23-007855EDGAR—
2022-03-252021-12-310000950170-22-004637EDGAR—
2021-03-042020-12-310001564590-21-011003EDGAR—
2020-03-052019-12-310001564590-20-008984EDGAR—
2019-03-142018-12-310001564590-19-007863EDGAR—
2018-03-092017-12-310001193125-18-077456EDGAR—
2017-03-102016-12-310001193125-17-078784EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-052025-09-300001193125-25-266969EDGAR23K words
2025-08-142025-06-300000950170-25-108797EDGAR—
2025-04-302025-03-310000950170-25-061222EDGAR—
2024-10-302024-09-300000950170-24-119100EDGAR—
2024-08-082024-06-300000950170-24-093733EDGAR—
2024-05-092024-03-310000950170-24-056965EDGAR—
2023-11-142023-09-300000950170-23-063517EDGAR—
2023-08-102023-06-300000950170-23-041293EDGAR—
2023-05-152023-03-310000950170-23-022187EDGAR—
2022-11-102022-09-300000950170-22-024223EDGAR—
2022-08-112022-06-300000950170-22-016917EDGAR—
2022-05-122022-03-310000950170-22-009590EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-190001193125-26-115119EDGAR3K words
2026-03-090001193125-26-098493EDGAR—
2026-02-270001193125-26-077646EDGAR—
2026-02-240001193125-26-065186EDGAR—
2026-01-220001193125-26-018664EDGAR—
2026-01-120001193125-26-010409EDGAR—
2025-12-170001193125-25-321738EDGAR—
2025-11-100001193125-25-273217EDGAR—
2025-11-050001193125-25-265702EDGAR—
2025-10-140001193125-25-237998EDGAR—

231 total filings indexed. 199 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Company Identity

CIK0001374690
TickerLRMR
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 462742d0e7ac21960193455c591745670f0924fe9415efd4bd7d0f0e1f4e688d
parent: 6778ac5475c442b061ade58cf3f4632a46e9fe0ca15d2c2ed7e05f5052323451
content hash: 31aa3a0e8778eba6ef78fa621396c6092b16df8782122a0fcca1406e3feb7a7e
signed: 2026-04-13T04:46:06.168Z
sources: 22 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf